IGFBP7-to-BNP Ratio for Differentiating HFpEF and HFrEF
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker-based methods are cumbersome and lack effectiveness in reliably distinguishing between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF, particularly due to the vague symptoms and limited diagnostic accuracy of existing markers like NT-proBNP.
Innovation Solution
The use of specific ratios, such as IGFBP7 to BNP-type peptide and the sum of IGFBP7+CRP to BNP-type peptide, for differentiating between HFpEF and HFrEF, providing a more accurate diagnostic method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing biomarkers like NT-proBNP are used for diagnosis, then the diagnostic process is simple, but the diagnostic accuracy and reliability are insufficient
Solution Approach 1:
The patent combines multiple biomarkers (IGFBP7, CRP, and NT-proBNP) into a composite diagnostic approach. By measuring all three markers and evaluating their combined patterns, the method achieves superior diagnostic accuracy for differentiating HFpEF from HFrEF compared to using any single marker alone, while maintaining clinical feasibility through standardized laboratory assays
2Reliability
If multiple biomarkers are used for assessment, then the diagnostic accuracy improves, but the method becomes more cumbersome
Solution Approach 1:
The patent transforms the diagnostic approach by changing from evaluating absolute biomarker levels to evaluating the pattern relationships between markers. Specifically, it uses the ratio of IGFBP7 to NT-proBNP and the combination pattern of all three markers (IGFBP7, CRP, NT-proBNP) to differentiate HFpEF from HFrEF. This parameter transformation simplifies interpretation while maintaining high reliability, as the relative patterns are more discriminatory than individual absolute values
3Adaptability or versatility
If single biomarker methods are used, then the procedure is straightforward, but the ability to distinguish between HFpEF and HFrEF is limited
Solution Approach 1:
The patent segments the diagnostic evaluation into distinct components: first measuring individual biomarker levels (IGFBP7, CRP, NT-proBNP), then analyzing their interrelationships through ratios and combined patterns. This segmentation allows the complex differentiation task to be broken down into manageable measurement steps followed by systematic analysis, improving versatility without proportionally increasing procedural complexity
Data Source
AI summary
The present invention relates to a method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide, and optionally of CRP (C-reactive protein) in a sample from the subject, calculating (i) a ratio of the amount of IGFBP7 and the amount of the BNP-peptide or (ii) a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide, comparing the ratio calculated with a reference ratio, and differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The present invention further concerns a method for the diagnosis of HFpEF.